MichaelGoode

[TimAlerts] Adam Feuerstein @adamfeuerstein $PBYI During extenet session q&a, doc in audience calls neratinib data "unactionable." Criticizes lack of follow up

MichaelGoode

[TimAlerts] Adam Feuerstein @adamfeuerstein $PBYI neratinib extenet study gets mediocre review from discussant. Small benefit but toxic. Need more follow up

MichaelGoode

[TimAlerts] $PBYI should spike when it reopens DJ PUMA BIOTECHNOLOGY ANNOUNCES PHASE III TRIAL OF PB272 IN EXTENDED ADJUVANT BREAST CANCER DEMONSTRATES STATISTICALLY SIGNIFICANT IMPROVEMENT IN DISEASE FREE SURVIVAL PBYI.N - DJN

Page
of 6